In MASLD, there is a decrease in endothelial nitric oxide synthase (eNOS) levels, leading to reduced synthesis of NO by the endothelium—an endogenous molecule known for its anti-atherogenic properties [13,14]. This evidence concerns the gene NOS3 and metabolic dysfunction-associated steatotic liver disease.